F18-FDG

DRUG2 trials

Sponsors

University Health Network, Toronto, National Cancer Institute (NCI)

Conditions

Hepatocellular CarcinomaNeuroendocrine Tumors

Phase 2

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

TerminatedNCT05009979

National Cancer Institute (NCI)Hepatocellular Carcinoma

Start: 2023-01-18End: 2024-11-20Updated: 2025-08-28

Unknown Phase

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Active, not recruitingNCT04804371

University Health Network, TorontoNeuroendocrine Tumors

Start: 2021-03-04End: 2027-02-22Target: 40Updated: 2026-03-23

Related Papers

Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma

PLoS ONE2022-11-117 citations